Abstract:A series of curcumin derivatives (1a–1h, 2a–2g, 3a–3c) were synthesized for suppression of castration‐resistant prostate cancer cells. Compounds 1f and 2g show similar androgen receptor suppression effect as compared to ASC‐J9 on C4‐2 cells; compound 3c displays significantly enhanced AR suppression effect as compared to ASC‐J9. In this work, a series of curcumin derivatives (1a–1h, 2a–2g, and 3a–3c) were synthesized for the suppression of castration‐resistant prostate cancer cells. All synthesized compounds were characterized by 1H NMR, 13C NMR, HRMS, and melting point. The in vitro cytotoxicity study shows that compounds 1a, 1e, 1f, 1h, 2g, 3a, and 3c display similar or enhanced cytotoxicity against 22Rv1 and C4‐2 cells as compared to ASC‐J9, other synthesized compounds display reduced cytotoxicity against 22Rv1 and C4‐2 cells as compared to ASC‐J9. Molecular docking simulation was performed to study the binding affinity and probable binding modes of the synthesized compounds with androgen receptor. The results show that all synthesized compounds exhibit higher cdocker interaction energies as compared to ASC‐J9. Compounds 1h, 2g, and 3c not only show strong cytotoxicity against 22Rv1 and C4‐2 cells but also exhibit high binding affinity with androgen receptor. In androgen receptor suppression study, compounds 1f and 2g show similar androgen receptor suppression effect as compared to ASC‐J9 on C4‐2 cells, compound 3c displays significantly enhanced AR suppression effect as compared to ASC‐J9, 1f and 2g. Compounds 1a, 1e, 1f, 1h, 2g, 3a and 3c prepared in this work have significant potential for castration‐resistant prostate cancer therapy.

Identification of the gossypol derivatives as androgen receptor inhibitor

Discovery and Identification of Pyrazolopyramidine Analogs as Novel Potent Androgen Receptor Antagonists

Discovery of Pyridine Tetrahydroisoquinoline Thiohydantoin Derivatives with Low Blood-Brain Barrier Penetration As the Androgen Receptor Antagonists.

Design, synthesis and biological evaluation of novel thiohydantoin derivatives as potent androgen receptor antagonists for the treatment of prostate cancer

Discovery of novel antagonists targeting the DNA binding domain of androgen receptor by integrated docking-based virtual screening and bioassays

Computationally Guided Discovery of Novel Non-Steroidal AR-GR Dual Antagonists Demonstrating Potency Against Antiandrogen Resistance.

Discovery of N -(4-(Benzyloxy)-phenyl)-sulfonamide Derivatives as Novel Antagonists of the Human Androgen Receptor Targeting the Activation Function 2

1,3-Disubstituted-1,2,4-triazin-6-ones with potent activity against androgen receptor-dependent prostate cancer cells

Design and synthesis of isothiocyanate-containing hybrid androgen receptor (AR) antagonist to downregulate AR and induce ferroptosis in GSH-Deficient prostate cancer cells

Design and Synthesis of Dual-Target Inhibitors Targeting Androgen Receptors and Glucocorticoid Receptors to Overcome Antiandrogen Resistance in Castration-Resistant Prostate Cancer

Novel Androgen Receptor Antagonist Identified by Structure-Based Virtual Screening, Structural Optimization, and Biological Evaluation.

Discovery of (2S)-N-(6-cyano-5-(trifluoromethyl)pyridin-3-yl)-3-(6-(4-cyanophenyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)-2-hydroxy-2-methylpropanamide As a Highly Potent and Selective Topical Androgen Receptor Antagonist for Androgenetic Alopecia Treatment

Synthesis of curcumin derivatives targeting androgen receptor for castration‐resistant prostate cancer therapy

Discovery of 5-Nitro-n-(3-(trifluoromethyl)phenyl) Pyridin-2-amine As a Novel Pure Androgen Receptor Antagonist Against Antiandrogen Resistance

Discovery of 2-(1-(3-chloro-4-cyanophenyl)-1h-pyrazol-3-yl)acetamides As Potent, Selective, and Orally Available Antagonists Targeting the Androgen Receptor

Discovery of Thiadiazoleamide Derivatives as Potent, Selective, and Orally Available Antagonists Disrupting Androgen Receptor Homodimer

Design, synthesis and biological evaluation of dual inhibitors targeting AR/AR-Vs and PARP1 in castration resistant prostate cancer therapy

1-Benzyloxy-5-phenyltetrazole derivatives highly active against androgen receptor-dependent prostate cancer cells

Spirocyclic Thiohydantoin Antagonists of F877L and Wild-Type Androgen Receptor for Castration-Resistant Prostate Cancer

Discovery of novel biphenyl derivatives as androgen receptor degraders for the treatment of enzalutamide-resistant prostate cancer

Identification of Oral Bioavailable Coumarin Derivatives as Potential AR Antagonists Targeting Prostate Cancer